158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details

臨床試験数 : 112 /  薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05604170
(ClinicalTrials.gov)		May 16, 20225/10/2022Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE)Tuberous Sclerosis ComplexDrug: GanaxoloneMarinus PharmaceuticalsNULLEnrolling by invitation1 Year65 YearsAll169Phase 3United States
2NCT05323734
(ClinicalTrials.gov)		April 1, 202221/3/2022Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyA Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC)Tuberous Sclerosis ComplexDrug: Ganaxalone;Drug: PlaceboMarinus PharmaceuticalsNULLRecruiting1 Year65 YearsAll162Phase 3United States;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
3NCT04285346
(ClinicalTrials.gov)		April 8, 202018/2/2020Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B)Tuberous SclerosisDrug: GanaxoloneMarinus PharmaceuticalsNULLCompleted2 Years65 YearsAll24Phase 2United States